Updates with share moves
** Shares of Telix Pharmaceuticals TLX.AX rise 2.8% to A$27.44
** Morningstar analysts expect TLX to receive a delayed regulatory approval, instead of a denial, for co's Pixclara, an imaging agent for glioma brain cancer
** Telix said on Monday that the U.S. Food and Drug Administration declined to approve its new drug application for Pixclara
** The FDA has requested additional clinical evidence to progress the application
** Brokerage expects the product to make first sales and contribute to earnings from 2026, instead of 2025
** FOrecasts no material effect on co over the medium term
** Stock rated "buy" on average; median price target stands at A$35, per data compiled by LSEG
** Stock last up 11.3%, YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。